3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
38
Neoplasm Metastasis
9
Brain Neoplasms
6
Stomach Neoplasms
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasms
2
Neoplasm, Residual
2
Meningeal Carcinomatosis
2
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Cancer With Brain Metastasis
2
Advanced Breast Cancer
2
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Inflammatory Breast Neoplasms
1
HER2-positive Breast Cancer
1
HER2-negative Breast Cancer
1
HER2 Overexpression
1
Glioblastoma
1
Gastric Adenocarcinoma
1
Drug-Related Side Effects and Adverse Reactions
1
Colonic Neoplasms
1
Breast Cancer Metastatic
1
Adenocarcinoma Of Esophagus
1
Interventions
Cyclophosphamide
21
Cytarabine
15
blinatumomab
13
fludarabine
12
Azacitidine
10
venetoclax
9
fludarabine phosphate
9
Blood Specimen Collection
8
Methotrexate
7
Lenalidomide
7
Dexamethasone
7
Rituximab
6
Mercaptopurine
6
Daunorubicin
6
Vincristine
5
daratumumab
4
Whole-Body Irradiation
4
Melphalan
4
Etoposide
4
Busulfan
4
obinutuzumab
3
Radiotherapy
3
Neoadjuvant Therapy
3
Maintenance
3
Liquid Biopsy
3
Immunotherapy, Adoptive
3
Idarubicin
3
Granulocyte Colony-Stimulating Factor
3
Drug Therapy
3
Doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasm, Residual
×
trastuzumab deruxtecan
×
Clear all
NCT06663787
2026-05-13
HER2 CR
Nagoya City University
Active not recruiting
50 enrolled
NCT05965479
2024-11-12
DECIPHER
University of Southampton
Phase 2
Recruiting
25 enrolled